Annovis Bio, Inc. filed a Form 8-K on November 4, 2026, disclosing a preliminary, unaudited estimate that its cash and cash equivalents were approximately $2.8 million as of September 30, 2026.

Key Highlights

  • Preliminary cash estimate: The company estimated cash and cash equivalents of approximately $2.8 million as of September 30, 2026.
  • Unaudited and subject to change: The estimate is preliminary, unaudited, and based on currently available information; quarterly financial closing processes for the period had not yet been completed.
  • No interim financials yet: The company's interim financial statements as of and for the three and nine months ended September 30, 2026 were not yet available at the time of filing.
  • Not reviewed by auditors: The company's independent registered public accounting firm did not conduct a review and expressed no opinion or assurance on these estimates.
  • CEO signatory: The filing was signed by Maria Maccecchini, Chief Executive Officer, on November 4, 2026.

Annovis Bio Discloses Preliminary September 30, 2026 Cash Position

Annovis Bio, Inc. (NYSE:ANVS), a Delaware-incorporated biopharmaceutical company headquartered in Malvern, PA, submitted a current report disclosing a preliminary cash figure ahead of the completion of its third-quarter 2026 financial close. According to the filing, the company estimates its cash and cash equivalents were approximately $2.8 million as of September 30, 2026, based on currently available information.

The company cautioned that the figure reflects preliminary estimates and that "the Company's actual results may differ from these estimates after the completion of financial closing procedures, final adjustments and review by the Company's staff and management." The filing also noted that the company "has not yet completed its quarterly financial closing processes for the period ended September 30, 2026," and that interim financial statements for the three and nine months ended September 30, 2026 were not yet available.

The filing stated that these preliminary estimates "should not be viewed as a substitute for full financial statements prepared in accordance with generally accepted accounting principles in the U.S." and are "not necessarily indicative of the results to be achieved for the stated period, or any other period." The company also indicated it does not undertake any obligation to publicly update or revise these preliminary estimates, except as required by law. The company directed readers to risk factors and management's discussion in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for further context.

What Was Disclosed

Annovis Bio disclosed a preliminary, unaudited estimate of approximately $2.8 million in cash and cash equivalents as of September 30, 2026, ahead of completing its Q3 2026 financial close. The estimate has not been reviewed by the company's independent auditors.